Ameriprise
IOVA icon

Ameriprise’s Iovance Biotherapeutics IOVA Stock Holding History

Ameriprise’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-38,515
Closed -$83.6K – 4145
2025
Q3 		$83.6K Buy
+38,515
New +$90.9K ﹤0.01% 3985
2025
Q2 		– Sell
-42,527
Closed -$142K – 4047
2025
Q1 		$142K Sell
42,527
-20,021
-32% -$103K ﹤0.01% 3836
2024
Q4 		$463K Sell
62,548
-494,986
-89% -$4.59M ﹤0.01% 3553
2024
Q3 		$5.24M Buy
557,534
+529,535
+1,891% +$5.02M ﹤0.01% 2347
2024
Q2 		$225K Sell
27,999
-23,997
-46% -$257K ﹤0.01% 3672
2024
Q1 		$771K Buy
51,996
+24,476
+89% +$285K ﹤0.01% 3277
2023
Q4 		$224K Buy
27,520
+1,085
+4% +$5.68K ﹤0.01% 3699
2023
Q3 		$120K Buy
+26,435
New +$173K ﹤0.01% 3776
2023
Q2 		– Sell
-143,013
Closed -$874K – 3953
2023
Q1 		$874K Sell
143,013
-1,168,247
-89% -$8.06M ﹤0.01% 3220
2022
Q4 		$8.38M Sell
1,311,260
-1,200,907
-48% -$9.38M ﹤0.01% 1890
2022
Q3 		$24.1M Sell
2,512,167
-497,847
-17% -$5.74M 0.01% 1072
2022
Q2 		$33.2M Buy
3,010,014
+488,509
+19% +$6.4M 0.01% 905
2022
Q1 		$42M Buy
2,521,505
+51,796
+2% +$801K 0.01% 885
2021
Q4 		$47.1M Buy
2,469,709
+298,109
+14% +$6.56M 0.01% 873
2021
Q3 		$53.6M Buy
2,171,600
+885,153
+69% +$20.9M 0.02% 740
2021
Q2 		$33.5M Buy
1,286,447
+832,124
+183% +$21.6M 0.01% 997
2021
Q1 		$14.4M Buy
454,323
+116,815
+35% +$4.84M ﹤0.01% 1574
2020
Q4 		$15.7M Buy
337,508
+91,843
+37% +$3.65M 0.01% 1416
2020
Q3 		$8.09M Buy
245,665
+234,775
+2,156% +$7.2M ﹤0.01% 1710
2020
Q2 		$292K Buy
10,890
+1,810
+20% +$59.5K ﹤0.01% 3371
2020
Q1 		$225K Buy
+9,080
New +$241K ﹤0.01% 3406
2018
Q2 		– Sell
-71,201
Closed -$1.2M – 3664
2018
Q1 		$1.2M Buy
+71,201
New +$1.08M ﹤0.01% 2895

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ameriprise's IOVA Position: Q4 2025 in Review

Ameriprise sold out of Iovance Biotherapeutics (IOVA) in Q4 2025, closing a stake of 38,515 shares — an estimated $83.6K sold.

Ameriprise first reported a position in IOVA in Q1 2018 and held it in 22 quarters. The position peaked at $53.6M in Q3 2021. 263 funds tracked by Wall St. Rank hold IOVA as of Q4 2025.

  • Ameriprise reported no remaining Iovance Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Ameriprise sold 38,515 Iovance Biotherapeutics shares in Q4 2025, an estimated $83.6K.
  • Ameriprise first reported a position in Iovance Biotherapeutics in Q1 2018 and held it in 22 quarters.
  • Ameriprise's Iovance Biotherapeutics position peaked at $53.6M in Q3 2021.
  • 263 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2025.

Based on Ameriprise's 13F filing for Q4 2025, filed 17 Feb 2026.